Physician profile
Suresh Ratnam
NPI 1649217639
$2,984,365.60
in general payments reported to CMS, 2019-2025
47 companies · $313K in 2025
The $313K reported for 2025 was more than what 99% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489K · 2020: $218K · 2021: $355K · 2022: $504K · 2023: $615K · 2024: $491K · 2025: $313K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $831K · Travel and Lodging: $276K · Honoraria: $164K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $81K · Consulting Fee: $46K · Food and Beverage: $22K · Education: $47.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $830,504.25 |
| Travel and Lodging | $275,529.48 |
| Honoraria | $163,503.36 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $80,685.00 |
| Consulting Fee | $45,784.10 |
| Food and Beverage | $21,973.25 |
| Education | $47.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $700,429.47 | 2019-2025 | Lynparza, Imfinzi, Enhertu |
| Incyte Corporation | $500,883.61 | 2019-2025 | Jakafi, Jakafi, Monjuvi |
| Exelixis INC. | $315,082.88 | 2019-2025 | Cabometyx |
| Lilly USA, LLC | $295,878.23 | 2019-2024 | Verzenio, Retevmo |
| Rigel Pharmaceuticals, INC. | $182,613.71 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Puma Biotechnology, INC. | $166,596.36 | 2019-2025 | Nerlynx |
| Jazz Pharmaceuticals INC. | $163,066.66 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $159,408.95 | 2020-2025 | Monoferric |
| E.R. Squibb & Sons, L.L.C. | $152,773.84 | 2019-2025 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $114,148.80 | 2020-2025 | Enhertu, Injectafer |
| Karyopharm Therapeutics INC. | $68,657.99 | 2023-2025 | Xpovio |
| Helsinn Therapeutics (U.S.), INC. | $31,805.07 | 2021-2022 | |
| Mirati Therapeutics, INC. | $29,241.41 | 2023-2024 | Krazati |
| Stemline Therapeutics INC. | $28,151.87 | 2023-2024 | Orserdu |
| Taiho Oncology, INC. | $21,427.87 | 2019-2023 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $17,355.98 | 2019-2020 | |
| Verastem, INC. | $10,418.31 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $7,036.63 | 2019-2025 | |
| Novocure INC. | $6,922.79 | 2023 | |
| Emd Serono, INC. | $6,921.75 | 2019 | |
| Coherus Oncology, INC. | $1,687.50 | 2023 | |
| Celgene Corporation | $1,339.06 | 2022-2025 | Reblozyl, Pomalyst |
| Glaxosmithkline, LLC. | $303.58 | 2022-2025 | Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $196.45 | 2019-2023 | Iclusig |
| Janssen Biotech, INC. | $187.76 | 2022-2025 | Rybrevant, Carvykti |
| Tempus Ai, INC | $184.66 | 2024 | |
| Adaptive Biotechnologies Corporation | $160.54 | 2022-2023 | Clonoseq |
| Medtronic, INC. | $153.06 | 2024-2025 | Osteocool Rf Ablation System |
| Sirtex Medical INC | $148.71 | 2023 | Sir-Spheres Microspheres |
| Astellas Pharma US INC | $136.09 | 2019-2025 | Vyloy, Xospata |
| Regeneron Healthcare Solutions, INC. | $131.77 | 2021-2024 | Libtayo |
| Epizyme, INC. | $124.84 | 2021 | |
| Genmab U.S., INC. | $115.89 | 2025 | Epkinly |
| Pfizer INC. | $110.22 | 2022-2025 | |
| Gilead Sciences, INC. | $102.99 | 2021-2025 | Trodelvy |
| Galvanize Therapeutics, INC | $91.06 | 2025 | Aliya System |
| Genentech USA, INC. | $70.69 | 2025 | Tecentriq, Itovebi |
| Eisai INC. | $64.21 | 2024-2025 | |
| Abbvie INC. | $59.49 | 2025 | |
| Seagen INC. | $57.71 | 2022-2023 | Padcev, Adcetris |
| Amgen INC. | $54.18 | 2022-2023 | Lumakras |
| Array Biopharma INC | $23.25 | 2025 | Mektovi, Braftovi, Lorbrena |
| Syndax Pharmaceuticals, INC. | $22.70 | 2025 | |
| Merck Sharp & Dohme LLC | $17.01 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Ratnam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.